Coexpression cluster:C1037
From FANTOM5_SSTAR
Full id: C1037_acute_medulloblastoma_Monocytederived_CD4_diffuse_testicular_small
Phase1 CAGE Peaks
| Hg19::chr14:73566082..73566112,+ | p@chr14:73566082..73566112 + |
| Hg19::chr14:73570051..73570166,+ | p@chr14:73570051..73570166 + |
| Hg19::chr14:73572641..73572756,+ | p4@RBM25 |
| Hg19::chr1:109241850..109241862,+ | p6@PRPF38B |
| Hg19::chr1:109241964..109241981,+ | p2@PRPF38B |
| Hg19::chr1:109241994..109242012,+ | p4@PRPF38B |
| Hg19::chr1:109242036..109242049,+ | p5@PRPF38B |
| Hg19::chr1:70710380..70710454,+ | p@chr1:70710380..70710454 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
| p.value | FDR | nGenes | nPathway | Name |
|---|---|---|---|---|
| 1.99497924496294e-05 | 0.0126282186206154 | 2 | 128 | Spliceosome (KEGG):03040 |
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
| GO ID | GO name | FDR corrected p-value |
|---|---|---|
| GO:0008380 | RNA splicing | 0.00102948989227113 |
| GO:0006397 | mRNA processing | 0.00102948989227113 |
| GO:0016071 | mRNA metabolic process | 0.00107790320168466 |
| GO:0006396 | RNA processing | 0.0019070019214864 |
| GO:0003729 | mRNA binding | 0.0128043276729378 |
| GO:0000375 | RNA splicing, via transesterification reactions | 0.0164674225721434 |
| GO:0000398 | nuclear mRNA splicing, via spliceosome | 0.0164674225721434 |
| GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 0.0164674225721434 |
| GO:0005681 | spliceosome | 0.0290367588376599 |
| GO:0016070 | RNA metabolic process | 0.0478583864116401 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
| Ontology term | p-value | n |
|---|---|---|
| hematopoietic oligopotent progenitor cell | 1.08e-10 | 165 |
| hematopoietic multipotent progenitor cell | 1.08e-10 | 165 |
| hematopoietic stem cell | 5.72e-10 | 172 |
| angioblastic mesenchymal cell | 5.72e-10 | 172 |
| nongranular leukocyte | 7.91e-09 | 119 |
| hematopoietic cell | 2.92e-08 | 182 |
| classical monocyte | 7.33e-08 | 45 |
| hematopoietic lineage restricted progenitor cell | 3.26e-07 | 124 |
| myeloid cell | 4.67e-07 | 112 |
| common myeloid progenitor | 4.67e-07 | 112 |
| CD14-positive, CD16-negative classical monocyte | 9.75e-07 | 42 |
| Ontology term | p-value | n |
|---|---|---|
| neural tube | 1.04e-07 | 57 |
| neural rod | 1.04e-07 | 57 |
| future spinal cord | 1.04e-07 | 57 |
| neural keel | 1.04e-07 | 57 |
| regional part of forebrain | 6.22e-07 | 41 |
| forebrain | 6.22e-07 | 41 |
| future forebrain | 6.22e-07 | 41 |
| Ontology term | p-value | n |
|---|---|---|
| cancer | 2.27e-24 | 235 |
| disease of cellular proliferation | 1.02e-23 | 239 |
| cell type cancer | 1.15e-11 | 143 |
| organ system cancer | 1.37e-11 | 137 |
| hematologic cancer | 1.60e-11 | 51 |
| immune system cancer | 1.60e-11 | 51 |
| leukemia | 7.18e-10 | 39 |
| carcinoma | 1.86e-08 | 106 |
| myeloid leukemia | 4.55e-07 | 31 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
| Motifs | -log10(p-value) |
|---|---|
|
{{{tfbs_overrepresentation_jaspar}}} |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
No analysis results for this cluster
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.
